MedPath

Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease

Phase 4
Terminated
Conditions
Crohns Disease
Bile Acid Malabsorption
Interventions
Drug: Placebo
Registration Number
NCT01203254
Lead Sponsor
Florian Beigel
Brief Summary

The purpose of this study is to assess the efficacy of cholestagel to reduce the frequency of soft and liquid stools per day in patients with CD in clinical remission with symptoms of BAM and to assess the improvement in stool consistency and quality of life in these patients and to assess the safety of cholestagel.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
34
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo-
CholestagelColesevelam-
Primary Outcome Measures
NameTimeMethod
Reduction of fluid stool > 30 %4 weeks after baseline
Secondary Outcome Measures
NameTimeMethod
Improvement of Stool Consistency4 weeks after baseline

Proportion of patients on cholestagel compared to placebo that reaches improvement of stool consistency on the Bristol stool chart of at least one point.

Improvement of Quality of Life.4 weeks after baseline

Proportion of patients on cholestagel compared to placebo that reaches an improvement of the Quality of Life.

Change of median liquid or soft stool frequency/per day.4 weeks after baseline

Trial Locations

Locations (6)

Praxis Dr. Mroß

🇩🇪

Berlin, Germany

Hochschulambulanz Med. Klinik I - Charite-

🇩🇪

Berlin, Germany

Hamburgisches Forschungsinstitut für CED

🇩🇪

Hamburg, Germany

Universitätsklinikum des Saarlandes -Innere Medizin-

🇩🇪

Homburg, Germany

Internistische Gemeinschaftspraxis

🇩🇪

Leipzig, Germany

CED - Zentrum der Universität München - Klinikum Grosshadern

🇩🇪

Munich, Germany

© Copyright 2025. All Rights Reserved by MedPath